Chris Hentschel joins, as new Chief Scientific Officer, the Cube Labs team.
Cube Labs is operating in the Italian landscape as the first mover in acceleration of academic R&D focusing on Biotech (oncology, rare diseases, nutraceuticals) and Medtech (medical devices, e-health, diagnostic).
Chris Hentschel is a molecular biologist and co-founder of The Ulysses Advisory Group. He has had pioneering and often transformative leadership roles in biosciences in the public sector (MRC Technology Transfer UK), in the private sector (Celltech, UK; Centocor, USA), in public-private partnerships (MRC Collaborative Centre, UK; Medicines for Malaria Venture, Switzerland) and later as a partner and chief scientist at Bio Istanbul.
A graduate in biochemistry from King’s College London, he began his career as an academic researcher at the National Institute for Medical Research (London, UK).
This led him to a series of research fellowships first in London, then as a European member of molecular biology at the Swiss Federal Institute of Technology in Zurich (ETHZ), and finally as a Fogarty Fellow at the National Cancer Institute (NIH, Bethesda, USA).
All this has allowed Hentschel to expand his experience and professional background until today, to get to work with a dynamic reality like Cube-Labs with great growth potential arising from the use of innovative technologies that bypass the classic scientific solutions.
Hentschel in his carrier closed a large number of deals in licensing out/in and M&A for more than 5 Billion $.